periotherapia
Osaka, JP · 1 known investors
Periotherapia develops antibody-based therapeutics targeting pathological periostin in the stromal environment to treat refractory diseases including cancer, diabetic retinopathy, and heart disease. The company, spun out from Osaka University, is conducting clinical trials for HER2-negative triple-negative breast cancer with support from Japan's AMED program.
Founders & leadership
YT
Yoshiaki TaniyamaDirector and Founder
ET
Eiji TaharaRepresentative Director, President, CEO and COO
Investors · 1
Frequently asked questions
- What does periotherapia do?
- Periotherapia develops antibody-based therapeutics targeting pathological periostin in the stromal environment to treat refractory diseases including cancer, diabetic retinopathy, and heart disease. The company, spun out from Osaka University, is conducting clinical trials for HER2-negative triple-negative breast cancer with support from Japan's AMED program.
- Who founded periotherapia?
- periotherapia was founded by Yoshiaki Taniyama.
- Who are periotherapia's investors?
- periotherapia's investors include Eisai Innovation, Inc..
- Where is periotherapia headquartered?
- periotherapia is headquartered in Osaka, JP.